ExpreS2ion Biotechnologies is a world leading CRO specialising in developing cell lines and processes based on Drosophila S2 cells. Our company has a proprietary and complete S2 recombinant protein expression platform: ExpreS2, which was developed over ten years at Pharmexa A/S.
ExpreS2 is a uniquely successful tool for non-viral, insect cell-based expression, and we are the only service company with in-depth practical experience in its use – both in preclinical development and in clinical trials.
The ExpreS2 platform is excellent in all phases of drug discovery, R&D and manufacturing as it offers fast access to protein and easy establishment of stable polyclonal pools. This results in high protein expression levels.
We have expressed a broad range of complex human, parasite and viral proteins in ExpreS2. Even proteins that have failed in other expression systems. We can also help you with a broad range of expression challenges, including heterodimers or trimers, virus-like particles (VLP) and low-expressing proteins, issues with broad glycosylation heterogeneity or issues with degradation of the desired protein by cellular proteases.
Stable protein expression
We can provide cell pellets/supernatants or purified protein from liter-scale cultures (shake flasks or bioreactors) in as little as 6 weeks after we receive your transfection-ready DNA. This service includes designing new gene constructs in our optimised expression vectors, stable cell line generation and protein production, which is verified using western blot analysis. We can supply you with the unpurified protein(s) or further purify them.
Services we provide
- Transient expression
- Medium throughput screening service
- Establishment of stable expression pools
- Production re-batching
- Selection of high-producing mini-pools and monoclonal cell lines
- Protein Purification
ExpreS2 TR, ExpreS2ion’s transfection reagent has been formulated and optimised for insect cell transfection. The performance of ExpreS2 TR in Sf9, Sf21, and S2 cells is superior to other commonly used transfection reagents, when compared head-to-head. ExpreS2 TR has also shown to be superior in transfection of mosquito cell lines.
Key applications and features
- Works perfectly in serum-containing and serum-free conditions
- Mix and add to cells – no need to change medium
- Customised batch sizes are available
Developing a robust process for protein production is critical for your vaccine or biotherapeutic development. ExpreS2ion has developed a number of processes that have been successfully transferred to commercial manufacturers. Through process development, we can considerably increase the protein yield, which reduces manufacturing costs.
We develop high-expressing monoclonal cell lines and robust processes. We support transfer to cGMP facilities. The robust ExpreS2 platform allows for various process modalities and intensification. This is why we have developed batch, fed-batch and perfusion processes using conventional bioreactors or single-use bioreactors. The characteristic robustness of the ExpreS2 system provides extra flexibility when transferring processes to cGMP facilities.
We offer fast assessment of expression feasibility in the ExpreS2 system, by transient screening expression of your proteins or protein variants: from transfection-ready DNA to a western blot result in 7 days. The feasibility studies are structured with go/stop decision points at critical steps. With ExpreS2, it takes only one week from DNA to protein detection.
The flexibility of performing transient expression, at a range of volumes from 96-deep well plates to liter scale, can fast track protein analytics. This provides fast access to protein, while the stable expressing pools, ready to use in 3-6 weeks, are the most efficient way of producing larger protein batches.
Transient screening: Find out in 7 days which of your proteins or protein variants are expressed. A range of options is then open for production of the selected proteins.
Stable expression screening: Starting with your gene(s) cloned into the ExpreS2vectors, we will test in a transient expression assay how your protein(s) express, while initiating the stable expression experiment. Within 7 days, a go/stop decision is taken, based on the results from transient expression. Upon a “go”� decision, results from stable expression will be available within 2-5 weeks. A go/stop decision at this point will be taken, regarding expansion of protein producing cell pool, possible selection of high expressers in ‘mini pools’ and the needed production volume.
ExpreS2ion Biotechnologies has not received any reviews.
ExpreS2ion Biotechnologies has not received any endorsements.